TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06476587

Intervention type: OTHER
Intervention: Vestibulo-sympathetic regulation test
Description: Participants will be seated on a rotating chair in the dark. Using a virtual reality headset, three visual stimuli will be presented: (A) no visual stimulus (darkness), (B) visual stimulus corresponding to a displacement of the participant along a cylindrical trajectory, (C) visual stimulus corresponding to a displacement of the participant along a conical trajectory. These 3 types of visual stimuli will be presented alone or during an Off-Vertical Axis Rotation (OVAR) with the chair axis inclined at an angle of 10° to the vertical and a rotation speed of 60°/s.~During each sequence, blood pressure, heart rate and end-tidal carbon dioxide (CO2) will be continuously recorded using standard medical equipment.

Intervention type: OTHER
Intervention: Sleep quality assessment
Description: Participants will have to complete five standardised clinical questionnaires: Pittsburgh Sleep Quality Index; Spiegel questionnaire assessing sleep quality; Morningness-Eveningness questionnaire; Insomnia Severity Scale; and Epworth Sleepiness Scale.~Moreover, the activity/rest rhythm will be measured continuously by actimetry over a period of 11 days.~The volunteer will also have to wear a Somno-Art® bracelet all night long during the eleven days of monitoring to collect the volunteer's actimetry and heart rate in order to specify which sleep stage the volunteer is in and thus monitor changes in sleep stages over the course of the night.~Finally, participants will have to complete a sleep diary.
Study: NCT06622330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positioning
Description: Children in the experimental group were given 30 minutes of wrapping and 30 minutes of fetal position after aspiration.
Study: NCT05173298

Intervention type: DRUG
Intervention: atezolizumab plus bevacizumab
Description: 1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
Study: NCT06596889

Intervention type: PROCEDURE
Intervention: Successful airway management
Description: * Types of equipment: Traditional oral airways, new airways, etc.~* Professional experience of the airway management practitioner (in years).~* If advanced, type of airway complication (bleeding, dental damage, mucosal damage, etc.), number of attempts~will be recorded separately for each patient.

Intervention type: PROCEDURE
Intervention: Successful airway management
Description: * Types of equipment: Traditional oral airways, new airways, etc.~* Professional experience of the airway management practitioner (in years).~* If advanced, type of airway complication (bleeding, dental damage, mucosal damage, etc.), number of attempts~will be recorded separately for each patient.
Study: NCT05982860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIND diet
Description: Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet has been established by Morris et al. (2015) to improve brain health, and reduce the risk or slow progression of neurodegenerative diseases. In this diet model, which is similar to the Mediterranean diet, the diet score changes according to the frequency of consumption of some foods. The more consumption of foods such as green leafy vegetables, other vegetables, berries, nuts, whole grains, fish (not fried), beans, poultry (not fried), and the limited consumption of butter/margarine, cheese, red meat and products, fast fried foods, and pastries \& sweets ensure more score. Also, regular consumption of wine (1 glass/d) and using olive oil as primary oil in meals increases the score. Berries, fish, and hardaliye (instead of wine) will be supplied to players as well as recommendations for consumption frequencies of food components in MIND diet to increase total score.
Study: NCT06033417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increased lifestyle walking (intervention)
Description: Participants will increase their baseline steps by a minimum of 3,000 extra steps/day, 5-days/week, for 8-weeks. Baseline steps will be assessed using a pedometer over a 7-day period before the intervention, after which a new (higher) daily step target will be assigned. The intervention will take place in the free-living setting, with participants reaching their step goals by engaging in more activities of daily living or via purposeful physical activity. Participants will wear a pedometer throughout the 8-week period to keep track of their steps, and adherence to the protocol will be determined by collecting the stored step data directly from each participant's pedometer on a weekly basis. Participants will be supported in their efforts to meet their daily step targets by engaging in once-weekly walking groups (30-mins/session) led by research staff. They will also receive 20-minute phone calls once every two weeks to set goals and create action plans for reaching their step targets.

Intervention type: OTHER
Group type: OTHER
Intervention: Health education only (control)
Description: Those randomized to the delayed participation group will be instructed to maintain their 'normal' lifestyle activities, thereby avoiding any significant increase in daily step counts beyond their 'baseline' values. Participants will wear a pedometer throughout the 8-week period to keep track of their steps, and adherence to the protocol will be determined by collecting the stored step data directly from each participant's pedometer on a weekly basis. Participants in this group will attend once-weekly group health education sessions (30-minutes/session), in addition to 5-minute, 'touch base' phone calls once every 2-weeks, but these phone calls will not involve goal-setting or action planning. After completing the initial 8-week period, these individuals can then opt to undertake the 'increased lifestyle walking' intervention of 3,000 extra steps/day over 5-days for 8-weeks if desired.
Study: NCT06476587

Intervention type: OTHER
Intervention: Representation of space and time assessment
Description: * Classic geometric illusions (inverted T, Mueller-Lyer, Ponzo, Poggendorff, Zoellner, Hering) which generate systematic distortions will be used.~* Time perception task: Participants will wear a virtual reality headset in which instructions will appear for 6 consecutive tasks each repeated 10 times with different durations.~* Perception of rotation amplitude and duration: Participants will be seated on a rotating chair, in complete darkness with noise-cancelling headphones. Participant will have to estimate the duration and the amplitude of rotations of the chair.~* Perceptual time constant: Participants will be seated on a rotating chair, in complete darkness, with a mask over their eyes and noise-cancelling headphones. After each chair rotation, participants will have to turn a crank every time the chair stops and reproduce their sensation of rotation in terms of direction (left or right) and intensity.
Study: NCT05323981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS627(210mg/7ml)
Description: Intravenous drip of 420mg HS627
Study: NCT05608668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pro2 - 60% of participant's MIP
Description: Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 60% of their MIP.
Study: NCT06476587

Intervention type: OTHER
Intervention: Representation of space and time assessment
Description: * Classic geometric illusions (inverted T, Mueller-Lyer, Ponzo, Poggendorff, Zoellner, Hering) which generate systematic distortions will be used.~* Time perception task: Participants will wear a virtual reality headset in which instructions will appear for 6 consecutive tasks each repeated 10 times with different durations.~* Perception of rotation amplitude and duration: Participants will be seated on a rotating chair, in complete darkness with noise-cancelling headphones. Participant will have to estimate the duration and the amplitude of rotations of the chair.~* Perceptual time constant: Participants will be seated on a rotating chair, in complete darkness, with a mask over their eyes and noise-cancelling headphones. After each chair rotation, participants will have to turn a crank every time the chair stops and reproduce their sensation of rotation in terms of direction (left or right) and intensity.

Intervention type: OTHER
Intervention: Influence of vestibular information on the bodily self-consciousness
Description: Participants will wear a virtual reality headset which allows them to be immersed in a virtual room similar in appearance to the one they are in. They will sit on a stool and hold a joystick in their hand. An avatar seen from behind, also sitting on a stool, will be presented in the centre of the virtual room approximately 2 m from them. The experimenter will touch several areas of the participant's back, over his clothes, with the end of the joystick. This movement will be reproduced by the virtual joystick in contact with the avatar's back, in two conditions: the synchronous condition, and the asynchronous condition.~After 2 min of stimulation, participants will perform a mental imagery task: a ball in the background of the virtual scene will roll towards them. After 3'', a black screen will appear and participants will have to imagine that the ball keeps moving towards them at the same speed. They will have to press the trigger when they think the ball has reached their level.
Study: NCT05608668

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pro2 - 15% of participant's MIP
Description: Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition
Study: NCT05323981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS627(420mg/14ml)
Description: Intravenous drip of 420mg HS627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perjeta
Description: Intravenous drip of 420mg PERJETA
Study: NCT05605652

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microosteoperforations
Description: Flapless micro-osteoperforations will be performed interproximally on the alveolar bone equidistant between upper right canine to upper left canine at every interdental alveolar bone except at the midline~alveolar bone to prevent trauma to the soft tissue frenum before placing the initial leveling archwire.
Study: NCT05608239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra aesthetic
Description: The goal of the study is to evaluate the volumizing and bio-stimulatory effects of sculptra injections in the temples with total volume of the diluted product as 9 ml (8 ml of sterile water and 1 ml of Lidocaine).
Study: NCT05443334

Intervention type: DRUG
Intervention: Semaglutide
Description: Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
Study: NCT06305624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connections App
Description: mobile application, a place where participants can find community and support to help them manage their ALD, learn liver health self-care, coping skills, and alcohol abstinence strategies.
Study: NCT05577715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-202
Description: Specified dose on specified days
Study: NCT06476587

Intervention type: OTHER
Intervention: 3 Tesla MRI
Description: The imaging evaluation will include an acquisition of anatomical images of the brain in its entirety and centred on the hippocampus.; and T2\*-weighted images sensitive to the blood-oxygen-level-dependent (BOLD) effect to assess functional brain activation during cognitive tasks and functional brain connectivity during rest.~For the functional activation sequences, three activation tasks will be performed, each lasting approximately 5 minutes: a mental rotation task, a time estimation task, and a prediction task.~These acquisitions will be combined with a collection of cardiorespiratory variables: respiratory movements and plethysmography. These signals will be used in the pre-processing of the functional MRI to remove physiological noise from the BOLD signal.

Intervention type: OTHER
Intervention: 3 Tesla MRI
Description: The imaging evaluation will include an acquisition of anatomical images of the brain in its entirety and centred on the hippocampus.; and T2\*-weighted images sensitive to the blood-oxygen-level-dependent (BOLD) effect to assess functional brain activation during cognitive tasks and functional brain connectivity during rest.~For the functional activation sequences, three activation tasks will be performed, each lasting approximately 5 minutes: a mental rotation task, a time estimation task, and a prediction task.~These acquisitions will be combined with a collection of cardiorespiratory variables: respiratory movements and plethysmography. These signals will be used in the pre-processing of the functional MRI to remove physiological noise from the BOLD signal.
Study: NCT06247540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT04530474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Pill
Description: Ivermecin as a one-time dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive medication as a one time dose
Study: NCT06247540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT, CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Receive IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Receive IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Receive PO
Study: NCT05497986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: HFNC with the maximum tolerated flow (up to 60 L/min). Titration of supplemental oxygen to a SpO2 between 88 - 92%.
Study: NCT04969744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICE
Description: Intermittent Cooling Exposure using cooling garment for 1-2 hours
Study: NCT05783674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Breaks® Video Exercises
Description: A total of at least 140 Brain Breaks® videos, each 3-4 minutes long, aerobic exercises including wide joint movements, movements specific to different sports branches such as yoga and volleyball, basketball, football, tennis, karate, judo, and warm-up-cooling movements. It includes national dances of different cultures. Horon, Zeybek, Scarf dance, morning gymnastics in Ürgüp Göreme, dribbling (volleyball, basketball), Pilates ball, and core area exercises. In each session, 2 videos will be applied and each will be repeated 2-3 times, and a 3-minute rest break will be given between each video. The total session will last for 20-30 minutes on average and physical activity will be performed twice a week, for a total of 8 weeks, 16 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Breaks® Video Exercises
Description: A total of at least 140 Brain Breaks® videos, each 3-4 minutes long, aerobic exercises including wide joint movements, movements specific to different sports branches such as yoga and volleyball, basketball, football, tennis, karate, judo, and warm-up-cooling movements. It includes national dances of different cultures. Horon, Zeybek, Scarf dance, morning gymnastics in Ürgüp Göreme, dribbling (volleyball, basketball), Pilates ball, and core area exercises. In each session, 2 videos will be applied and each will be repeated 2-3 times, and a 3-minute rest break will be given between each video. The total session will last for 20-30 minutes on average and physical activity will be performed twice a week, for a total of 8 weeks, 16 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posture training
Description: All participants, as the BB Video Exercise and Control Group, will be given a 20-minute hands-on training on the importance of proper posture once at the beginning of the study, and breathing control training will be given to maintain proper sitting, standing, lying postures, and proper posture.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posture training
Description: All participants, as the BB Video Exercise and Control Group, will be given a 20-minute hands-on training on the importance of proper posture once at the beginning of the study, and breathing control training will be given to maintain proper sitting, standing, lying postures, and proper posture.
Study: NCT05497986

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional low flow oxygenation
Description: Conventional oxygenation through nasal prongs or a facemask, with supplemental oxygen titrated to a SpO2 between 88 - 92%.
Study: NCT04752813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPM31510
Description: Subjects will receive a weekly, 96-h infusion of BPM31510 for a duration of 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin K1
Description: Subjects will receive prophylactic Vitamin K1 at a recommended dose of 10 mg Intramuscularly prior to the beginning of each week of BPM31510 therapy.
Study: NCT05061355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heart valve surgery
Description: Heart valve surgery will be performed as soon as possible and preferably within 48 hours
Study: NCT04752813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent TMZ 75 mg/m2 once daily (qd) × 42 days. Subjects will receive the standard TMZ treatment for additional 6 cycles post BPM31510 treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent standard RT for 42 days.
Study: NCT06562816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trypsin-Chymotrypsin
Description: 100000 IU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium 550mg
Description: 550mg
Study: NCT05280314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IO102-IO103
Description: IO102-IO103 is a combination of an indoleamine 2,3-dioxygenase 1 (IDO1) peptide (IO102) and a programmed death-ligand 1 (PD-L1) peptide (IO103), emulsified with an adjuvant (Montanide ISA 51 VG).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IO102-IO103
Description: IO102-IO103 is a combination of an indoleamine 2,3-dioxygenase 1 (IDO1) peptide (IO102) and a programmed death-ligand 1 (PD-L1) peptide (IO103), emulsified with an adjuvant (Montanide ISA 51 VG).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IO102-IO103
Description: IO102-IO103 is a combination of an indoleamine 2,3-dioxygenase 1 (IDO1) peptide (IO102) and a programmed death-ligand 1 (PD-L1) peptide (IO103), emulsified with an adjuvant (Montanide ISA 51 VG).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab KEYTRUDA®
Description: Pembrolizumab KEYTRUDA® administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab KEYTRUDA®
Description: Pembrolizumab KEYTRUDA® administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab KEYTRUDA®
Description: Pembrolizumab KEYTRUDA® administered intravenously
Study: NCT06171490

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP2-4mg
Description: NP2-4 mg is a new product containing tobacco-derived nicotine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP2-4mg
Description: NP2-4 mg is a new product containing tobacco-derived nicotine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP2-4mg
Description: NP2-4 mg is a new product containing tobacco-derived nicotine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP2-4mg
Description: NP2-4 mg is a new product containing tobacco-derived nicotine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP2-6 mg
Description: NP2-6 mg is a new product containing tobacco-derived nicotine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP2-6 mg
Description: NP2-6 mg is a new product containing tobacco-derived nicotine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP2-6 mg
Description: NP2-6 mg is a new product containing tobacco-derived nicotine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP2-6 mg
Description: NP2-6 mg is a new product containing tobacco-derived nicotine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Loz-4mg
Description: The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Loz-4mg
Description: The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.
Study: NCT05187533

Intervention type: OTHER
Group type: OTHER
Intervention: Osteopathic protocol of Sphenopalatine Ganglion Stimulation
Description: Sphenopalatine Ganglion Stimulation to improve lacrimal and salivary gland secretion to improve ocular and oral dryness

Intervention type: OTHER
Group type: OTHER
Intervention: Osteopathic protocol of Sphenopalatine Ganglion Stimulation
Description: Sphenopalatine Ganglion Stimulation to improve lacrimal and salivary gland secretion to improve ocular and oral dryness

Intervention type: OTHER
Group type: OTHER
Intervention: Osteopathic protocol of Sphenopalatine Ganglion Stimulation
Description: Sphenopalatine Ganglion Stimulation to improve lacrimal and salivary gland secretion to improve ocular and oral dryness